Caris Life Sciences (CAI) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Market opportunity and technology leadership

• Precision oncology and molecular medicine are rapidly advancing, with significant market opportunities at both institutional and individual oncologist levels.

• The platform features whole exome, whole transcriptome, and is expanding to whole genome sequencing, with over a million profiles and 200,000 patients profiled last year.

• The company is the only provider with FDA-approved whole exome and transcriptome technology, aiding partnerships, research, and reimbursement.

• New products include Caris ChromoSeq for hematological malignancies and Caris MI Clarity for early-stage breast cancer, leveraging extensive datasets and AI tools.

• The Precision Oncology Alliance now includes 100 member institutions, supporting research and clinical programs.

Data assets, AI, and clinical utility

• The dataset exceeds a million genomic profiles, with 728,000 transcriptomes, most matched with clinical outcomes.

• AI-driven tools like GPSai assist in cancer diagnosis and therapy selection, with high accuracy for cancer of unknown primary and misdiagnosed cases.

• Comprehensive sequencing enables detection of mutations, gene signatures, and supports rapid updates for new biomarkers.

• The platform's lookback program notifies physicians of new biomarker approvals, enhancing patient care without extra cost.

• Digital pathology and AI algorithms are used for early recurrence detection and risk assessment in breast cancer.

Product pipeline and innovation

• Caris Detect, a whole genome-based early cancer detection test, showed 60.3% sensitivity and 99.2% specificity in initial studies.

• Caris ChromoSeq consolidates multiple tests for hematological malignancies into one, with a seven-day turnaround.

• MI Clarity, an AI-based pathology test, predicts breast cancer recurrence risk up to 15 years post-diagnosis.

• Ongoing development includes MRD approaches and expansion of liquid biopsy capabilities.

• Pharma partnerships leverage the large dataset for drug target discovery, highlighted by a major deal with Genentech.